The top-line results showed no decline in cognition scores in patients with mild Alzheimer's disease who received simufilam continuously for 24 months. "We're fighting Alzheimer's disease by testing simufilam, a new type of drug that has a completely different mechanism of action from monoclonal antibody drug treatments," said Remi Barbier, CEO of Cassava.